Initiation of ribociclib — Competitive Intelligence Brief

Initiation of ribociclib (Initiation of ribociclib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CDK inhibitor. Area: Oncology.

phase 2 CDK inhibitor CDK4/6 Oncology Small molecule

Target snapshot

Initiation of ribociclib (Initiation of ribociclib) — Shirley Vichy Wang. CDK4/6 inhibitor

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Initiation of ribociclib TARGET	Initiation of ribociclib	Shirley Vichy Wang	phase 2	CDK inhibitor	CDK4/6
Ibrance	Palbociclib	Pfizer	marketed	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)	2015-01-01
Palbociclib in combination with AI	palbociclib-in-combination-with-ai	Pfizer	marketed	CDK inhibitor	CDK4/6
target treatment	target treatment	Institut Bergonié	marketed	CDK4/6 inhibitor	CDK4/6
Abemaciclib + Aromatase Inhibitor	Abemaciclib + Aromatase Inhibitor	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + Aromatase inhibitor combination	CDK4/6 + Aromatase
Palbociclib	palbociclib	Pfizer Inc.	marketed	CDK4/6 inhibitor	Cyclin-dependent kinases 4 and 6 (CDK4/6)
Abemaciclib + Fulvestrant	Abemaciclib + Fulvestrant	Prof. Wolfgang Janni	marketed	CDK4/6 inhibitor + estrogen receptor antagonist	CDK4/6 and estrogen receptor (ER)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CDK inhibitor class)

1. Astellas Pharma Europe B.V. · 1 drug in this class
2. Dyve Biosciences, Inc. · 1 drug in this class
3. Pfizer · 1 drug in this class
4. Shirley Vichy Wang · 1 drug in this class
5. Tego Science, Inc. · 1 drug in this class